



Oddelenie klinickej onkológie
Špecializovaná nemocnica sv. Svorada Zobor
Kláštorská 134
949 88 Nitra

("HCO")

Bratislava, 4th May 2020

Dear madam/sir,

Takeda Pharmaceuticals Slovakia s.r.o., registered address Plynárenská 7/B, 821 09 Bratislava, ID No.: 31 368 832, registered in the commercial registry maintained by the Municipal court in Prague under Filé No. C 25754, ("**Takeda**") is a manufacturer of pharmaceutical and diagnostic products focusing on research, development, manufacture, distribution, marketing and sale of pharmaceutical products.

As a key player in the healthcare environment, Takeda acknowledges the need to support healthcare providers in the joint fight against coronavirus.

As the safety of medical staff and patients is the main priority, Takeda will provide the following equipment "KN95 masks (FFP2 equivalent)" in no. of 200 pieces ("**Equipment**") free of charge to the HCO for use in accordance with its purpose and under the terms set out in this letter.

The estimated cost of the Equipment is EUR 572 excl. VAT.

The Equipment is provided in order to secure safety of the HCO's staff while performing their duties ("**Purpose**")

The Equipment is provided to the HCO and must remain in its possession. The equipment is not and Takeda does not consider it to be an individual's personal benefit.

Takeda declares that the Equipment is not provided as an incentive for its products to be purchased, ordered, prescribed, recommended or otherwise given preferential treatment.

Takeda undertakes no liability for any potential manufacturing, functional or legal defects of the Equipment. Relatedly, Takeda hereunder assigns to the HCO any and all claims by law, which are available to the buyer against the seller, as regards any liability for any potential defects.

Oddelenie klinickej onkológie
Špecializovaná nemocnica sv. Svorada Zobor, n.o.
Kláštorská 134
949 88 Nitra

("Zariadenie")

Bratislava, 4. máj 2020

Vážená pani, vážený pán,

spoločnosť Takeda Pharmaceuticals Slovakia s.r.o., so sídlom Plynárenská 7/B, 821 09 Bratislava, IČO: 31 368 832, zapísaná v obchodnom registri vedenom Okresným súdom Bratislava I, oddiel: Sro, vložka číslo 668 I/B ("**Takeda**") je výrobcom farmaceutických a diagnostických výrobkov sústreďujúcim sa na výskum, vývoj, výrobu, distribúciu, marketing a predaj farmaceutických výrobkov

Ako kľúčový hráč v oblasti zdravotníctva, spoločnosť Takeda vidí potrebu podporiť poskytovateľa zdravotnej starostlivosti v spoločnom boji proti koronavírusu.

Pretože bezpečnosť zdravotníckeho personálu a pacientov je prvoradá, poskytne spoločnosť Takeda zadarmo pre Zariadenie nasledujúce vybavenie „respirátory KN95 (FFP2 ekvivalent)" v počte kusov 200 („Vybavenie") pre použitie v súlade s jeho účelom a za podmienok stanovených v tomto liste.

Odhadovaná cena Vybavenia je 572 EUR bez DPH.

Vybavenie je poskytované za účelom zaistenia bezpečnosti personálu Zariadenie v súvislosti s plnením jeho pracovných povinností ("**Účel**").

Vybavenie sa poskytuje v prospech Zariadenia a musí zostať v jeho vlastníctve. Vybavenie nie je a spoločnosť Takeda ho nepovažuje za osobný prospech žiadneho jednotlivca

Spoločnosť Takeda prehlasuje, že Vybavenie neposkytuje ako stimul na to, aby jej produkty boli kupované, objednávané, predpisované, odporúčané či aby sa im dostalo iného preferenčného zaobchádzania.

Spoločnosť Takeda nepreberá žiadnu zodpovednosť za prípadné výrobné, funkčné alebo právne vady Vybavenie. V súvislosti s tým spoločnosť Takeda postupuje Zariadenie všetky zákonné nároky, ktoré má kupujúci voči predávajúcemu k dispozícii, pokiaľ ide o akúkoľvek zodpovednosť za prípadné chyby.



Takeda undertakes no liability for any direct and indirect damage caused to any third party, which is related directly or indirectly with the use of the Equipment.

By signing this letter, you confirm having read and understood its provisions, agree to the terms and conditions set forth herein and you are authorized to execute the same. In the same time, you confirm accepting the donation from Takeda in the meaning set forth in applicable tax laws.

By signing this letter, you also acknowledge that Takeda shall publish the details of this donation in accordance with laws and regulations that apply to its activities.

In the case of any discrepancies between the language versions, the Slovak version shall prevail.

Spoločnosť Takeda nezodpovedá za žiadne priame ani nepriame škody spôsobené akejkoľvek tretej strane, ktoré sú priamo alebo nepriamo spojené s používaním Vybavenie.

Podpisom tohto listu potvrdzujete, že ste si preštudoval jeho ustanovenia, rozumiete im, súhlasíte s podmienkami tu zakotvenými a ste oprávnený ho podpísať. Zároveň týmto potvrdzujete prijatie daru od spoločnosti Takeda v zmysle príslušných daňových predpisov.

Podpisom tohto listu zároveň beriete na vedomie, že spoločnosť Takeda zverejní detaily tohto daru v súlade s predpismi, ktoré sa vzťahujú na jej činnosť,

V prípade akýchkoľvek rozdielov medzi jazykovými verziami má prednosť slovenská verzia.

Takeda Pharmaceuticals Slovakia s.r.o.

Juraj Varga
Prokurista

Tomáš Laluha
Prokurista

Praha

Plače & dâte / Miesto a dátum

Bratislava

Plače & dâte / Miesto a dátum

**Oddelenie klinickej onkológie
Špecializovaná nemocnica sv. Svorada**

MUDr. Plamen Kabaivanov
Riaditeľ

Nitra

Place & date / Miesto a dátum

Certifikát dokončenia

ID obálky: 84861BD24C3744E085172C85F361C5AE
Predmet: Takeda darovací list - poprosíme o podpis cez DocuSign (04)
Obálka zdroja:
Stránky dokumentu: 2
Stránky certifikátu: 4
AutoNav: Povolené
Pečiatkovanie ID obálky: Povolené
Časové pásmo: (UTC+01:00) Belgrade, Bratislava, Budapest, Ljubljana, Prague

Stav: Dokončené

Pôvodca obálky:
Kamila Fecko
40 Landsdowne Street
Cambridge, MA 02139
kamila.fecko@takeda.com
Adresa IP: 85.216.157.172

Sledovanie záznamu

Stav: Originál
12 mája 2020 | 16:08
Majiteľ: Kamila Fecko
kamila.fecko@takeda.com

Umiestnenie: DocuSign

Udalosti signatára

Plamen Kabaivanov
sekretariat@snzobor.sk
Úroveň zabezpečenia: E-mail, Overenie konta
(žiadne)

Podpis

Prijatie podpisu: Vopred vybraný štýl
Pomocou adresy IP: 84.16.37.173

Časová pečiatka

Odoslané: 12 mája 2020 | 16:11
Znova poslať: 12 mája 2020 | 16:20
Znova poslať: 18 mája 2020 | 11:31
Znova poslať: 26 mája 2020 | 19:07
Zobrazené: 05 júna 2020 | 07:55
Podpísané: 05 júna 2020 | 07:56

Elektronický záznam a informácie o podpise:
Prijaté: 05 júna 2020 | 07:55
ID:d79203c8-c6cf-435a-8d08-c2509502aff3

Udalosti signatára s osobnou účasťou

Podpis

Časová pečiatka

Udalosti doručenia editora

Stav

Časová pečiatka

Udalosti doručenia agenta

Stav

Časová pečiatka

Udalosti doručenia sprostredkovateľa

Stav

Časová pečiatka

Udalosti certifikovaného doručenia

Stav

Časová pečiatka

Udalosti kópie

Stav

Časová pečiatka

Udalosti svedka

Podpis

Časová pečiatka

Udalosti notára

Podpis

Časová pečiatka

Udalosti súhrnu obálky

Stav

Časové pečiatky

Odoslanie obálky
Certifikované a doručené
Podpísanie je dokončené
Dokončené
S algoritmom hash/šifrovaním
Zabezpečenie skontrolované
Zabezpečenie skontrolované
Zabezpečenie skontrolované

26 mája 2020 | 19:07
05 júna 2020 | 07:55
05 júna 2020 | 07:56
05 júna 2020 | 07:56

Platobné udalosti

Stav

Časové pečiatky

Elektronický záznam a informácie o podpise

ELECTRONIC RECORD AND SIGNATURE DISCLOSURE

From time to time, Takeda Pharmaceuticals - Platform (we, us or Company) may be required by law to provide to you certain written notices or disclosures. Described below are the terms and conditions for providing to you such notices and disclosures electronically through the DocuSign systém. Please read the information below carefully and thoroughly, and if you can access this information electronically to your satisfaction and agree to this Electronic Record and Signature Disclosure (ERSD), please confirm your agreement by selecting the check-box next to 'I agree to use electronic records and signatures' before clicking 'CONTINUE' within the DocuSign systém.

Getting paper copies

At any time, you may request from us a paper copy of any record provided or made available electronically to you by us. You will have the ability to download and print documents we send to you through the DocuSign systém during and immediately after the signing session and, if you elect to create a DocuSign account, you may access the documents for a limited period of time (usually 30 days) after such documents are first sent to you. After such time, if you wish for us to send you paper copies of any such documents from our office to you, you will be charged a \$0.00 per-page fee. You may request delivery of such paper copies from us by following the procedure described below.

Withdrawing your consent

If you decide to receive notices and disclosures from us electronically, you may at any time change your mind and tell us that thereafter you want to receive required notices and disclosures only in paper format. How you must inform us of your decision to receive future notices and disclosure in paper format and withdraw your consent to receive notices and disclosures electronically is described below.

Consequences of changing your mind

If you elect to receive required notices and disclosures only in paper format, it will slow the speed at which we can complete certain steps in transactions with you and delivering services to you because we will need first to send the required notices or disclosures to you in paper format, and then wait until we receive back from you your acknowledgment of your receipt of such paper notices or disclosures. Further, you will no longer be able to use the DocuSign systém to receive required notices and consents electronically from us or to sign electronically documents from us.

All notices and disclosures will be sent to you electronically

Unless you tell us otherwise in accordance with the procedures described herein, we will provide electronically to you through the DocuSign system all required notices, disclosures, authorizations, acknowledgements, and other documents that are required to be provided or made available to you during the course of our relationship with you. To reduce the chance of you inadvertently not receiving any notice or disclosure, we prefer to provide all of the required notices and disclosures to you by the same method and to the same address that you have given us. Thus, you can receive all the disclosures and notices electronically or in paper format through the paper mail delivery system. If you do not agree with this process, please let us know as described below. Please also see the paragraph immediately above that describes the consequences of your electing not to receive delivery of the notices and disclosures electronically from us.

How to contact Takeda Pharmaceuticals - Platform:

You may contact us to let us know of your changes as to how we may contact you electronically, to request paper copies of certain information from us, and to withdraw your prior consent to receive notices and disclosures electronically as follows:

To contact us by email send messages to: ad.ministrayter@mail.com

To advise Takeda Pharmaceuticals - Platform of your new email address

To let us know of a change in your email address where we should send notices and disclosures electronically to you, you must send an email message to us at ad.ministrayter@mail.com and in the body of such request you must state: your previous email address, your new email address. We do not require any other information from you to change your email address.

If you created a DocuSign account, you may update it with your new email address through your account preferences.

To request paper copies from Takeda Pharmaceuticals - Platform

To request delivery from us of paper copies of the notices and disclosures previously provided by us to you electronically, you must send us an email to ad.ministrayter@mail.com and in the body of such request you must state your email address, full name, mailing address, and telephone number. We will bill you for any fees at that time, if any.

To withdraw your consent with Takeda Pharmaceuticals - Platform

To inform us that you no longer wish to receive future notices and disclosures in electronic format you may:

i. dedine to sign a document from within your signing session, and on the subsequent page, select the check-box indicating you wish to withdraw your consent, or you may;

ii. send us an email to ad.ministrayter@mail.com and in the body of šuch request you muřt state your email, full name, mailing address, and telephone number. We do not need any other information from you to withdraw consent.. The consequences of your withdrawing consent for online documents will be that transactions may také a longer time to process..

Required hardware and software

The minimum systém requirements for using the DocuSign systém may change over time. The current systém requirements are found here: <https://support.docusign.com/guides/signer-guide-signing-svstem-requirements>.

Acknowledging your access and consent to receive and sign documents electronically

To confirm to us that you can access this information electronically, which will be similar to other electronic notices and disclosures that we will provide to you, please confirm that you háve read this ERSD, and (i) that you are able to print on paper or electronically save this ERSD for your future reference and access; or (ii) that you are able to email this ERSD to an email address where you will be able to print on paper or save it for your future reference and access. Further, if you consent to receiving notices and disclosures exclusively in electronic formát as described herein, then select the check-box next to 'I agree to use electronic records and signatures' before clicking 'CONTINUE' within the DocuSign systém.

By selecting the check-box next to 'I agree to use electronic records and signatures', you confirm that:

- You can access and read this Electronic Record and Signatúre Disclosure; and
- You can print on paper this Electronic Record and Signatúre Disclosure, or save or send this Electronic Record and Disclosure to a location where you can print it, for future reference and access; and
- Until or unless you notify Takeda Pharmaceuticals - Platform as described above, you consent to receive exclusively through electronic means all notices, disclosures, authorizations, acknowledgements, and other documents that are required to be provided or made available to you by Takeda Pharmaceuticals - Platform during the course of your relationship with Takeda Pharmaceuticals - Platform.